Literature DB >> 35261217

Evaluation and simplification of risk factors in FIGO 2000 scoring system for gestational trophoblastic neoplasia: a 19-year retrospective analysis.

Yang Weng1, Yuanyuan Liu1, Chitapa Benjoed1, Xiaodong Wu2, Sangsang Tang1, Xiao Li2,3, Xing Xie2,3, Weiguo Lu4,5,6.   

Abstract

OBJECTIVES: The International Federation of Gynecology and Obstetrics (FIGO) 2000 scoring system classifies gestational trophoblastic neoplasia (GTN) patients into low- and high-risk groups, so that single- or multi-agent chemotherapy can be administered accordingly. However, a number of FIGO-defined low-risk patients still exhibit resistance to single-agent regimens, and the risk factors currently adopted in the FIGO scoring system possess inequable values for predicting single-agent chemoresistance. The purpose of this study is therefore to evaluate the efficacy of risk factors in predicting single-agent chemoresistance and explore the feasibility of simplifying the FIGO 2000 scoring system for GTN.
METHODS: The clinical data of 578 GTN patients who received chemotherapy between January 2000 and December 2018 were retrospectively reviewed. Univariate and multivariate logistic regression analyses were carried out to identify risk factors associated with single-agent chemoresistance in low-risk GTN patients. Then, simplified models were built and compared with the original FIGO 2000 scoring system.
RESULTS: Among the eight FIGO risk factors, the univariate and multivariate analyses identified that pretreatment serum human chorionic gonadotropin (hCG) level and interval from antecedent pregnancy were consistently independent predictors for both first-line and subsequent single-agent chemoresistance. The simplified model with two independent factors showed a better performance in predicting single-agent chemoresistance than the model with the other four non-independent factors. However, the addition of other co-factors did improve the efficiency. Overall, simplified models can achieve favorable performance, but the original FIGO 2000 prognostic system still features the highest discrimination.
CONCLUSIONS: Pretreatment serum hCG level and interval from antecedent pregnancy were independent predictors for both first-line and subsequent single-agent chemoresistance, and they had greater weight than other non-independent factors in predicting single-agent chemoresistance. The simplified model composed of certain selected factors is a promising alternative to the original FIGO 2000 prognostic system, and it shows comparable performance.

Entities:  

Keywords:  Chemoresistance; Gestational trophoblastic neoplasia (GTN); Risk factor; Single-agent chemotherapy

Mesh:

Year:  2022        PMID: 35261217      PMCID: PMC8913924          DOI: 10.1631/jzus.B2100895

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  36 in total

1.  FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  2002-06       Impact factor: 3.561

Review 2.  Staging and classification of gestational trophoblastic disease.

Authors:  Barry William Hancock
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2003-12       Impact factor: 5.237

3.  Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.

Authors:  Woo Dae Kang; Ho Sun Choi; Seok Mo Kim
Journal:  Gynecol Oncol       Date:  2010-03-29       Impact factor: 5.482

4.  Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.

Authors:  Eloise Chapman-Davis; Anna V Hoekstra; Alfred W Rademaker; Julian C Schink; John R Lurain
Journal:  Gynecol Oncol       Date:  2012-03-23       Impact factor: 5.482

5.  Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.

Authors:  Woo Dae Kang; Cheol Hong Kim; Moon Kyoung Cho; Jong Woon Kim; Hye Yon Cho; Yoon Ha Kim; Ho Sun Choi; Seok Mo Kim
Journal:  Int J Gynecol Cancer       Date:  2010-11       Impact factor: 3.437

6.  Methotrexate with citrovorum factor rescue in gestational trophoblastic disease.

Authors:  L C Wong; Y C Choo; H K Ma
Journal:  Am J Obstet Gynecol       Date:  1985-05-01       Impact factor: 8.661

7.  Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.

Authors:  Elza Maria Hartmann Uberti; Maria do Carmo Fajardo; Adriana Gerhardt Vieira da Cunha; Sirlene Soares Frota; Antônio Braga; Antonio Celso Koehler Ayub
Journal:  Rev Bras Ginecol Obstet       Date:  2015-06

8.  Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.

Authors:  M C Winter; J A Tidy; A Hills; J Ireson; S Gillett; K Singh; B W Hancock; R E Coleman
Journal:  Gynecol Oncol       Date:  2016-10-15       Impact factor: 5.482

9.  Evaluation of prognostic factors and staging in gestational trophoblastic tumor.

Authors:  J T Soper; A C Evans; M R Conaway; D L Clarke-Pearson; A Berchuck; C B Hammond
Journal:  Obstet Gynecol       Date:  1994-12       Impact factor: 7.661

10.  Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide dataset.

Authors:  Y K Eysbouts; P B Ottevanger; L F A G Massuger; J IntHout; D Short; R Harvey; B Kaur; N J Sebire; N Sarwar; F C G J Sweep; M J Seckl
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.